Forty Seven Finds $75M For Cancer Drugs
Menlo Park-based Forty Seven, a developer of oncology drugs based on antibodies, has raised $75M in a Series B funding, the company said this week. The funding was led by Wellington Management Company, and also included Clarus Ventures, Lightspeed Venture Partners, Sutter Hill Ventures, and GV (Google Ventures). Forty Seven says it is developing an antibody, Hu5F9‐G4, which "takes the brakes off macrophages". The company is in Phase 1b/2 trial in patients with solid tumors, leukemia, or lymphoma.
posted on Thursday, October 19, 2017 (Link to more information)
Related companies:
Forty Seven Inc.
Related stories:
> Forty Seven Finds $32.5M For Cancer Antibodies
> ACT Biotech Gets $12M For Cancer Drugs
> ORIC Pharmaceuticals Gets $53M For Cancer Drugs
> POC Medical Systems Finds $21M For Breast Cancer Screening
> Proteolix Takes $79M In Third Round
silicontap.com Home